The structure of the reaction products was established.”
“Purpose: To use differential scanning calorimetry
(DSC) to predict the liquefaction time and dissolution profile of some commercial paracetamol suppositories as well as paracetamol suppositories formulated with palm oil base.
Methods: The suppository base OSI-906 concentration was prepared by mixing hydrogenated palm oil and palm kernel stearin in a ratio of 8:2. Three commercial paracetamol suppositories (A, B, and C) were purchased, while product D, paracetamol suppository was formulated with suppository base using the double casting method. In-vitro drug release from suppositories was determined using DSC and the effect of liquefaction on drug release was studied. The relationship between suppository melting and dissolution was analysed statistically.
Results: The melting temperature of products A and B were 41.0 and 40.0 degrees C respectively, whereas those of products C and D were 35.9 and 33.1 degrees C, respectively. The liquefaction time of the suppositories were 61.4 (A), 54.2 (B), 9.0 (C) and 7.4 min (D). Less than 40 % paracetamol was released from products A and B in 2 h, while products
C and D showed good dissolution with > 95 % drug release in 15 min. Statistical analysis using Pearson’s test indicates that the proportion of melt in the suppository base correlates well with drug release (p < 0.05).
Conclusion: Paracetamol release from check details palm oil suppositories is rapid and correlates with melting of the base. DSC can be used to predict drug release in paracetamol suppository formulations.”
“Introduction.
Pevonedistat This study examined the influence of diabetes on left ventricular hypertrophy (LVH) detected by different electrocardiographic (ECG) criteria and its changes induced by a 12-month candesartan-based regimen.
Methods. The patients were treated for a 12-month period with a candesartan-based regimen (8/16 mg + hydrochlorothiazide 12.5 mg + additional drugs to target blood pressure < 140/90 mmHg [< 130/80 in diabetics]). Cornell voltage index (CorV), Cornell product (CorP), Sokolow-Lyon voltage index (SokV), and Sokolow-Lyon product (SokP) were calculated. In total 276 patients were included, 51 with diabetes.
Results. At study end, blood pressure was reduced 19.0+/-9.2/7.3+/-3.4 mmHg in diabetic patients and 18.8+/-9.1/8.0+/-3.2 mmHg in nondiabetic subjects (both p<0.01 vs. baseline; p=0.85 between groups). At baseline, 37.5% of diabetic and 26.4% of non-diabetic patients fulfilled criteria of ECG-LVH by CorP (p=0.02), 25.7% and 23.2%, respectively, by SokP (p=0.18), 11.8% and 13.7% by CorV (p=0.16), and 14.3% and 11.6% by SokV (p=0.10). At study end, the prevalence of ECG-LVH was reduced to 25.1% (relative risk reduction [RRR] 33.3%, p=0.001) and 18.2% (RRR 29.2%, p=0.